Skip to content

  • Development Pipeline

    Development-stage programs in gout, cancer and HIV
  • Gout

    First and next-generation URAT1 transporter inhibitors for the treatment of hyperuricemia and gout
  • Cancer

    Mitogen-activated ERK kinase (MEK) inhibitors for the treatment of cancer, being developed under a global license agreement with Bayer Healthcare AG
  • HIV

    First and next-generation non-nucleoside reverse transcriptase inhibitors (NNRTIs), for the treatment of HIV

Scientific Publications

Scientific publications, posters and presentations relating to Ardea Biosciences’ proprietary research programs or research collaborations with other biotechnology or pharmaceutical companies will be posted once they are available.

Company Presentations

Ardea Company Update, August 6, 2010 Ardea Company Update,
August 6, 2010